Demetra Holding Acquires Majority Stake in GetSet Surgical, Expanding Spine Portfolio
Demetra Holding, a pioneering and independent international medical device company specializing in anti-infective cements, spacers, and biomaterials for orthopedic applications, has announced its strategic acquisition of a 51% stake in GetSet Surgical, a leading Swiss-based provider of spine surgery solutions. This move represents a major milestone in Demetra Holding’s long-term growth strategy, reinforcing its commitment to innovation, infection management, and enhanced operational efficiency in hospitals and ambulatory surgical centers (ASCs).
Strategic Rationale for the Acquisition
The acquisition of a majority stake in GetSet Surgical marks a significant expansion of Demetra Holding’s footprint in the spine sector. By integrating GetSet’s advanced sterile-packaged spine sets with Demetra’s extensive portfolio, the company aims to provide cutting-edge solutions that minimize infection risks, improve efficiency in surgical procedures, and support environmentally sustainable healthcare practices. This collaboration underscores the shared vision of both companies to advance patient safety and optimize surgical workflows in spine and orthopedic care.
“The integration of GetSet’s state-of-the-art, sterile-packaged spine sets with Demetra Holding’s robust portfolio and resources will significantly enhance our shared commitment to minimizing infection risks and optimizing operational efficiency in hospitals and the emerging ASC market,” said Ole Stoklund, Founder and CEO of GetSet Surgical.
By combining their expertise, Demetra and GetSet will create a comprehensive spine and orthopedic product range designed to meet the evolving demands of healthcare providers and patients worldwide. The emphasis on single-use, sterile-packaged implants and instruments will help address key challenges associated with hospital-acquired infections and central sterilization bottlenecks, ultimately leading to improved clinical outcomes and reduced healthcare costs.
Benefits of the Acquisition
The strategic acquisition of GetSet Surgical is expected to deliver multiple benefits, both from a clinical and business perspective. Key advantages include:
- Enhanced Infection Control: The use of sterile-packaged, single-use instruments and implants significantly reduces the risk of surgical site infections, aligning with Demetra Holding’s mission to lead in infection management solutions.
- Operational Efficiency: Hospitals and ASCs will benefit from streamlined workflows, reduced reliance on central sterilization, and optimized surgical procedures, leading to lower costs and improved resource allocation.
- Environmental Sustainability: The transition to single-use, sterile-packaged spine implants and instruments reduces the need for repeated sterilization cycles, thereby minimizing water and energy consumption, lowering medical waste, and supporting environmentally conscious healthcare practices.
- Market Expansion: The acquisition strengthens Demetra Holding’s global market presence, particularly in the high-growth spine segment, allowing the company to serve a broader customer base with innovative, high-quality solutions.
Michele Perrino, CEO of Demetra Holding, highlighted the strategic significance of the acquisition, stating: “Demetra Holding is proud to be at the forefront of this collaboration, as it aligns perfectly with our mission to improve healthcare solutions focused on orthopedic infection management strategies worldwide. By combining GetSet Surgical’s innovative capabilities with our existing product offering, we aim to become the first choice for surgeons and their patients in the sterile, single-use packaged spine procedure market.”
Global Expansion Strategy and U.S. Market Focus
As part of its global expansion strategy, Demetra Holding is prioritizing the introduction of GetSet Surgical’s products into the U.S. market, leveraging its newly established U.S. Spine Division under its portfolio company, OsteoRemedies. The division will oversee the distribution of GetSet’s advanced spine solutions, with an initial focus on FDA-cleared products and upcoming innovations.
Ted Bird, an industry veteran recently appointed as Vice President Spine Commercial at OsteoRemedies, will spearhead the expansion efforts in the U.S. market. The initial product lineup will include:
- GoPLF!™ Posterior Lateral Fusion System: Already FDA-cleared and set for immediate market introduction.
- GoLIF!™ Lumbar Interbody Fusion System: Expected to launch later this year, pending FDA 510(k) clearance.
- Future Innovations: Additional spine solutions currently in development will be accelerated through the investment, further solidifying ’s leadership in the sector.
The expansion into the U.S. represents a critical step for Demetra Holding, given the country’s significant demand for advanced spinal surgery solutions and the growing emphasis on infection control and surgical efficiency. By leveraging its strong distribution network and expertise, Demetra aims to establish itself as a key player in the North American spine market.
Integration into Demetra Holding’s Global Infrastructure
Beyond the U.S., Demetra Holding is committed to expanding GetSet Surgical’s innovative solutions across global markets. Both the GoPLF!™ and GoLIF!™ systems are already CE-marked, making them available for distribution in Europe and other international regions. By integrating GetSet Surgical’s product offerings into its extensive global infrastructure, Demetra Holding is poised to drive innovation and improve patient outcomes worldwide.
The acquisition aligns seamlessly with Demetra Holding’s broader vision of enhancing surgical efficiency, reducing infection risks, and promoting sustainable healthcare practices. With a strong focus on research and development, Demetra continues to invest in next-generation medical technologies that address critical challenges in orthopedic and spine surgery.
Source Link
